



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/025,967

12/26/2001

Shigeru Kamei

087147-0443B

2213

22428 7590 12/22/2006
FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

EXAMINER

LUKTON, DAVID

ART UNIT

PAPER NUMBER

1654

| SHORTENED STATUTORY PERIOD OF RESPONSE | MAIL DATE | DELIVERY MODE |
|--|-----------|---------------|
|--|-----------|---------------|

3 MONTHS

12/22/2006

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

18

| | | | |
|------------------------------|------------------------|---------------------|--|
| Office Action Summary | Application No. | Applicant(s) | |
| | 10/025,967 | KAMEI ET AL. | |
| | Examiner | Art Unit | |
| | David Lukton | 1654 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 September 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10 and 17-25 is/are pending in the application.
- 4a) Of the above claim(s) 4-10 and 17-25 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Pursuant to the directives of the response filed 9/29/06, claim 1 has been amended. Claims 1-10 and 17-25 remain pending. Claims 4-10 and 17-25 remain withdrawn from consideration. Claims 1-3 are examined in this Office action.

Applicants' arguments filed 9/29/06 have been considered and found not persuasive.



Claims 1-3 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 5,480,868. Although the conflicting claims are not identical, they are not patentably distinct from each other. In response, applicants have argued that if the examiner is willing to issue a notice of allowability, applicants would, at that point, be willing to file a terminal disclaimer. However, as applicants counsel may be aware, it is customary for applicants to overcome rejections prior to issuance of a notice of allowability, rather than subsequent thereto. The rejection is maintained.



The following is a quotation of the first paragraph of 35 U.S.C. §112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3 are rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicants have asserted that the compound (recited in the last four lines of claim 1) is an LH-RH antagonist. However, there is no evidence that this is the case. Certainly, other antagonists of LH-RH are known. But the reality in pharmacology is that one cannot "predict" receptor antagonism or even receptor binding merely by viewing the structure of a compound. Minor changes in structure can result in elimination of activity. As stated in *Ex parte Forman* (230 USPQ 546, 1986) and *In re Wands* (8 USPQ2d 1400, Fed. Cir., 1988) the factors to consider in evaluating the need (or absence of need) for "undue experimentation" are the following: quantity of experimentation necessary, amount of direction or guidance presented, presence or absence of working examples, nature of the invention, state of the prior art, relative skill of those in that art, predictability or unpredictability of the art, and breadth of the claims.

Given the unpredictability of structure/activity relationships, "undue experimentation" would be required of the skilled artisan to use the composition of claim 1 to antagonize LH-RH.

The rejection is maintained.



Claim 1 is objected to. The structural formula is not clearly legible. The examiner can determine applicants' intentions with regard to the structures. However, the persons charged with the task of printing the final document may be unwilling to issue the patent if the structures are unclear. Accordingly, a notice of allowability will not be issued as long as one or more of the structures is unclear.



Claims 1-3 are rejected under 35 U.S.C. §112 second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites that the peptide can be any that falls within the scope of the generic formula. At the same time, the claim recites that the peptide is limited to the specie recited in the last four lines of the claim. Thus, the question is, which limitation controls? Given the ambiguity, claims 2-3 are similarly rejected.



The following is a quotation of 35 U.S.C. §103 which forms the basis for all obviousness rejections set forth in the Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section §102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section §102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made, absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103.

Claims 1-3 are rejected under 35 U.S.C. §103 as being unpatentable over Haviv (USP 5,110,904) in view of Deasy (USP 4,874,612) or Hutchinson (USP 4,789,726).

As indicated previously, Haviv discloses (cols 12-25) various peptides falling within the scope of instant claim 1. Also disclosed (col 27, line 8+) is that the peptide can be combined with a PLA/PLG copolymer. Haviv does not suggest selecting a polydispersity that is somewhere in the range of 1.2-4. Each of the secondary references discloses PLA/PGA copolymers that have the requisite polydispersity. For example, this is disclosed in Deasy at col 2, line 45+. Hutchinson even goes a step further in arguing (col 2, line 51+; col 3, line 53+) that a polydispersity of about 2 is the most statistically probable distribution of molecular weights. A practitioner of the Haviv invention may or may not see an advantage in a polydispersity of 2, but would recognize that such a composition is most likely to be obtained.

In response to the foregoing, applicants have amended claim 1 to recite that the peptide ^{be} can one of those falling within the scope of the generic formula, and at the same time, the peptide must be the specie that is recited in the last four lines of the claim. However, it is not clear which of these two limitations controls. Given the ambiguity, it is

appropriate to maintain this rejection.



Claims 1-3 are rejected under 35 U.S.C. §103 as being unpatentable over Haviv (USP 5,110,904) in view of Boswell (USP 3,773,919) further in view of either Deasy (USP 4,874,612) or Hutchinson (USP 4,789,726).

The teachings of the references were indicated previously. In response to this rejection, applicants have amended claim 1 to recite that the peptide can be one of those falling within the scope of the generic formula, and at the same time, the peptide must be the species that is recited in the last four lines of the claim. However, it is not clear which of these two limitations controls. Given the ambiguity, it is appropriate to maintain this rejection.



No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached at (571)272-0562. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.



DAVID LUKTON, PH.D.
PRIMARY EXAMINER